Comprehensive Review on Febuxostat for Hyperuricemia with Gout: Insights from Current Practice and Clinical Trials
- 26.12.2025
- Review article
- Verfasst von
- Claudio Borghi
- Federica Piani
- Athanasios L. Manolis
- Erschienen in
- High Blood Pressure & Cardiovascular Prevention
Abstract
Hyperuricemia is a metabolic disorder associated with an increased risk of gout, chronic kidney disease (CKD), and cardiovascular disease (CVD). The management of hyperuricemia in conditions where urate deposition has already occurred primarily relies on xanthine oxidase inhibitors (XOIs), such as allopurinol and Febuxostat. Febuxostat, a non-purine selective XOI, has demonstrated superior urate-lowering efficacy, particularly in patients with renal impairment. This review provides an in-depth analysis of Febuxostat’s pharmacological properties, clinical efficacy, and safety profile, with a focus on cardiovascular and nephroprotective effects.
Anzeige
- Titel
- Comprehensive Review on Febuxostat for Hyperuricemia with Gout: Insights from Current Practice and Clinical Trials
- Verfasst von
-
Claudio Borghi
Federica Piani
Athanasios L. Manolis
- Publikationsdatum
- 26.12.2025
- Verlag
- Springer International Publishing
- Erschienen in
-
High Blood Pressure & Cardiovascular Prevention
Print ISSN: 1120-9879
Elektronische ISSN: 1179-1985 - DOI
- https://doi.org/10.1007/s40292-025-00777-y
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.